Evaluation of chemotherapy-induced nausea and vomiting in pediatric patients with high-grade glioma treated with lomustine —a case series
ConclusionIn this case series, we identified lomustine as a highly emetogenic chemotherapeutic agent. According to the current guidelines, CINV prophylaxis with a 5-HT3 receptor antagonist in combination with dexamethasone and (fos)aprepitant is recommended.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
More News: Brain Tumor | Cancer | Cancer & Oncology | Chemotherapy | Children | Dexamethasone | Glioma | Pediatrics